Abel et al. observed [18] ERBB3 activation due to vemurafenib treatment; however they saw activation via FOXD3. Chandarlapaty et al. [54] identified ERBB3 activation in response to AKT inhibition via phosphorylated FOXO3 in cancer cell lines from multiple tumor types, which were resistant to AKT inhibition. Here, ERBB3 is linked to neoplasm.